26th Apr 2016 08:40
LONDON (Alliance News) - AstraZeneca PLC on Tuesday said it has signed a licensing agreement with Ironwood Pharmaceuticals covering exclusive US rights for Zurampic.
Zurampic treats hyperuricemia associated with uncontrolled gout.
Ironwood will acquire the exclusive US rights to Zurampic and will get the US rights for a fixed-dose combination of lesinurad and allopurinol.
Ironwood will pay AstraZeneca sales-related and other milestones of up to USD265.0 million and royalties on product sales.
Separately, AstraZeneca late on Monday said the US Food & Drug Administration has approved Bevespi Aerosphere for treating sufferers of chronic obstructive pulmonary disease.
The product is a twice-daily, fixed-dose treatment and is the first product to be approved using the drugmaker's Co-Suspension technology, which allows the delivery of one or more different medicines from a single inhaler.
"LAMA/LABAs are emerging as a preferred treatment option for many COPD patients. This class aims to provide maximum bronchodilation, which enables patients to breathe better and may help them be more active," said Sean Bohen, executive vice-president of global medicines development and chief medical officer at AstraZeneca.
AstraZeneca shares were down 1.1% to 4,040.5 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca